<DOC>
	<DOCNO>NCT01701063</DOCNO>
	<brief_summary>The purpose study assess safety , efficacy , pharmacokinetics carefully monitor cohort pediatric subject infect hepatitis C virus ( HCV ) telaprevir-based regimen Part A dose adjustment need Part B .</brief_summary>
	<brief_title>An Open-Label Study Effect Telaprevir Combination With Peginterferon Alfa-2b Ribavirin Pediatric Subjects Infected With Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Males female age 3 17 year age Chronic hepatitis C Hepatitis C virus genotype 1a b Screening Visit Subject judge good health ( besides HCV infection ) opinion investigator . Signed informed consent form ( ICF ) , appropriate , sign Assent Form History prior evidence medical condition associate chronic liver disease HCV Body weight &lt; 15 kg &gt; 90 kg Prior evidence hepatic decompensation Contraindications pegylated interferon/ribavirin ( PegIFN/RBV ) History evidence severe retinopathy clinically significant ophthalmological disorder History nongenotype 1 HCV Participation investigational drug study describe Study Protocol Use prohibit drug within 7 day 5 halflives first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>